Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)
| Market Cap | $75.28M-66.0% |
| Revenue (ttm) | $0-100.0% |
| Net Income | -$44.07M-305.0% |
| EPS | -$0.76-311.1% |
| Shares Out | 57.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 673,414 |
| Open | $1.33 |
| Previous Close | $1.39 |
| Day's Range | $1.31 - $1.40 |
| 52-Week Range | $1.31 - $3.97 |
| Beta | 3.46 |
| Analysts | Buy |
| Price Target | $8.00(+510.69%) |
| Earnings Date | Mar 15, 2027 |
About BDTX
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Analyst consensus
1 firm rating BDTX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 15, 2027Earnings report
$BDTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BDTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BDTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BDTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BDTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BDTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BDTX
| VTIVanguard Morningstar Total Stock Market ETF | $2.05M |
| IWMiShares Russell 2000 ETF | $1.63M |
| VXFVanguard Extended Market ETF | $1.07M |
| FESMFidelity Enhanced Small Cap ETF | $920.52K |
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $751.87K |
| SMLFiShares U.S. Small-Cap Equity Factor ETF | $672.81K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BDTX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive Phase 2 results and FDA feedback supporting registration pathway for lead drug silevertinib outweigh routine conference participation announcements.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.18% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.12% |
| STSB | iShares Factors US Small Blend Style ETF | 0.07% |
| BSVO | EA Bridgeway Omni Small-Cap Value ETF | 0.02% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.01% |
| IBB | iShares Biotechnology ETF | 0.01% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.00% |
Weight is the stock’s share of each fund’s holdings.
